Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Lung Neoplasms 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Urothelial Cancer 1Urinary Bladder Diseases 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1

Interventions

Ipilimumab 4tremelimumab 1tilsotolimod 1durvalumab 1Vemurafenib 1Vaccination 1Surgical Procedures, Operative 1Nivolumab 1Melphalan 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diabetes Mellitus, Insulin-Dependent, 12 × durvalumab × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡